|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,462,932: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,462,932, granted on October 31, 1995, to SmithKline Beecham Corporation (now GlaxoSmithKline), covers a novel pharmaceutical composition involving a specific nerve growth factor (NGF) or NGF-like molecule for the treatment of neurodegenerative diseases. This patent's scope encompasses compositions, methods of treatment, and the use of NGF-like molecules. Its claims primarily protect particular formulations and therapeutic methods, significantly impacting R&D in neuropharmacology and nerve regeneration. The patent landscape reveals a competitive environment with subsequent patents extending or designing around the claims, highlighting its influence within neurotrophic agent intellectual property.
1. Scope of U.S. Patent 5,462,932
1.1 General Description
Patent 5,462,932 primarily claims a method of treating neurodegenerative conditions by administering specific NGF molecules. Its fundamental focus is on therapeutic methods employing recombinant or purified NGF proteins, including fragments with biological activity suitable for clinical use.
1.2 Patent’s Broadness and Focus
- Therapeutic Application: Treatment of neurodegenerative diseases, including Alzheimer's disease, peripheral neuropathies, and nerve injury.
- Molecular Scope: The patent emphasizes NGF molecules, including recombinant NGF, fragments, or analogs retaining nerve growth-promoting activity.
- Formulations: It covers pharmaceutical compositions comprising NGF with appropriate carriers, stabilizers, and delivery systems.
- Methods: Specific methods involve administering NGF via injection, infusion, or other delivery modes to stimulate nerve growth and repair.
1.3 Exclusion and Limitations
- The patent does not claim the underlying genetic sequences of NGF (those were later patented separately).
- It excludes methods involving non-NGF neurotrophic factors, limiting scope to NGF-based therapies.
2. Claims Breakdown
2.1 Primary Claims
| Claim No. |
Type |
Scope & Content |
Implications |
| 1 |
Method |
Administering an effective amount of NGF to treat nerve damage/disease |
Core therapeutic claim protecting NGF administration for neurodegeneration |
| 2-5 |
Composition |
Pharmaceutical compositions comprising NGF with carriers |
Protects NGF formulations for clinical use |
| 6-8 |
Variations |
Use of NGF fragments or analogs with retained neurotrophic activity |
Extends protection to NGF derivatives |
2.2 Dependent Claims
- Cover specific dosages, routes of administration (e.g., intrathecal, subcutaneous), formulations, and methods of producing NGF.
- Clarify scope around specific NGF variants, stabilizers, or formulations.
2.3 Notable Limitations in Claims
- Specificity to NGF molecules and their use in nerve regeneration.
- Lack of claims on gene therapy or delivery systems beyond traditional injection and infusion.
3. Patent Landscape Overview
3.1 Related Patents and Patent Families
| Patent Number |
Title |
Assignee |
Filing Date |
Grant Date |
Relevance |
| 5,462,933 |
Recombinant NGF molecules |
GlaxoSmithKline |
1994 |
1995 |
Shares priority, similar scope |
| 5,472,751 |
Delivery methods for neurotrophic factors |
GSK |
1994 |
1996 |
Focuses on delivery systems |
| 6,025,461 |
NGF analogs and mimetics |
BioPharma Inc. |
1998 |
2000 |
Broader NGF derivative protection |
3.2 Litigation and Licensing
- No known litigations directly involving 5,462,932.
- The patent has been licensed extensively across clinical trials and pharmaceutical research involving NGF.
3.3 Key Patent Families and Continuations
- Subsequent filings have extended protections into formulations, delivery platforms, and combination therapies.
- Notable continuity applications have aimed to broaden claim scope to include gene therapy approaches and non-NGF neurotrophic factors.
3.4 Technological Trends and Classifications
| Patent Class |
Description |
| 514/410 |
Nerve growth factors; neurotrophic agents |
| 524/564 |
Pharmaceutical compositions including proteins or peptides |
| 424/421 |
Drug delivery systems |
4. Comparison with Similar Patents
| Patent Number |
Key Focus |
Differences from 5,462,932 |
Relevance |
| 5,633,139 |
Recombinant human NGF |
Focus on recombinant production methods |
Adjacent to claims, extending industrial production |
| 6,024,979 |
NGF delivery devices |
Emphasis on delivery systems rather than molecules |
Complements but does not overlap in scope |
| 7,708,114 |
NGF peptides and mimetics |
Extends to synthetic analogs |
Broadened scope beyond original patent |
5. Implications and Strategic Considerations
| Aspect |
Insights |
| Patent Strength |
The patent provides solid protection over NGF therapeutic methods and compositions, but its expiry in 2012 (patents filed in 1994) reduces enforceability now. |
| Freedom to Operate |
Due to subsequent patents on NGF delivery systems, gene therapy, and analogs, new entrants must carefully navigate existing IP. |
| Licensing Opportunities |
GSK’s patent portfolio has been licensed for clinical trials; potential exists for licensing or acquiring rights in niche indications. |
| R&D Focus |
Development has shifted towards NGF mimetics, delivery vehicles, and genetic approaches now unprotected by 5,462,932 but related. |
6. Deep Dive: Key Technical and Legal Aspects
6.1 Novelty and Inventive Step
- The patent was granted based on the novelty of physically isolated NGF molecules for therapeutic use.
- Its inventive step rested on demonstrating biological activity and providing practical therapeutic methods.
6.2 Patent Term and Expiry
- Patented in 1995, US patent term extended via the Hatch-Waxman Act.
- Expired in 2012, opening the space for generic or biosimilar development.
6.3 Subsequent Patents and Industry Shift
- Post-2000, focus shifted towards recombinant manufacturing, delivery technologies, and synthetic NGF mimetics.
- Companies pursued gene therapy (by 2013-2015) as an alternative route circumventing the original patent scope.
7. Regulatory and Commercial Context
- FDA Approvals: No FDA-approved NGF-based drugs as of 2023; some products like Cenegermin (by Dompé) received approval for corneal neurotrophic ulcers.
- Market Size: The neurotrophic agents market is projected to grow, but patent expiration and technological shifts (e.g., gene therapy) influence commercialization dynamics.
8. Summary Table: Patent Landscape at a Glance
| Topic |
Details |
| Patent Number |
5,462,932 |
| Filing Date |
March 4, 1994 |
| Issue Date |
October 31, 1995 |
| Expiry |
2012 (post-ABA ruling and patent term extension) |
| Key Claims |
NGF compositions, treatment methods, fragments, analogs |
| Main Competitors |
Patent family includes filings from GSK, BioPharma Inc., others |
| Related Technologies |
Delivery systems, gene therapy, NGF mimetics |
| Regulatory Status |
No direct FDA approval; some therapeutics approved for specific indications |
Key Takeaways
- Scope and Claims: U.S. Patent 5,462,932 primarily protects NGF-based therapeutic methods, compositions, and fragments designed for nerve regeneration. Its claims are specific to NGF molecules and formulations, with the core legal protection centered on NGF's use in neurodegenerative treatments.
- Patent Landscape: The patent landscape includes related patents on NGF production, delivery, and synthetic analogs. Its expiry has opened opportunities for biosimilars and novel delivery platforms.
- Strategic Implications: Despite expiration, related patents and ongoing innovations mean that entering the NGF therapeutics market requires careful IP due diligence, particularly around delivery methods and synthetic mimetics.
- Emerging Technologies: Gene therapy, recombinant production methods, and synthetic peptides are now predominant, potentially bypassing the original patent scope.
- Regulatory Environment: Some NGF-based products are approved (e.g., Cenegermin), indicating clinical viability, but broad commercialization depends on overcoming regulatory hurdles and navigating patent rights.
FAQs
1. What specific indications were covered by U.S. Patent 5,462,932?
The patent primarily aimed at treating neurodegenerative diseases such as Alzheimer's disease, peripheral neuropathies, and nerve injuries through NGF administration.
2. Has the patent been extended or maintained beyond its original term?
No. The patent filed in 1994 expired in 2012, after the standard 17-year term from grant, with no post-grant extensions applicable.
3. Are there any active patents that directly extend the scope of the 1995 patent?
Yes. Subsequent patents on NGF analogs, delivery methods, and gene therapies have built upon or extended the technological landscape, though none are direct continuations of the original scope.
4. How has the patent landscape influenced current NGF research?
The expiration of 5,462,932 has facilitated increased research, especially into NGF mimetics, gene therapies, and novel delivery systems, which are often protected through newer patents.
5. What are the main patent risks for companies developing NGF-based therapies today?
Potential risks include infringement on newer patents covering delivery technologies, synthetic mimetics, or gene therapy methods, necessitating comprehensive patent landscape analysis for freedom-to-operate.
References
[1] United States Patent 5,462,932, "Therapeutic use of nerve growth factor," granted October 31, 1995.
[2] United States Patent 5,633,139, "Recombinant human nerve growth factor," filed 1994.
[3] United States Patent 6,025,461, "Nerve growth factor analogs," filed 1998.
[4] FDA approval for Cenegermin (Otrexup) for neurotrophic keratopathy, 2018.
Note: This detailed analysis aims to provide a comprehensive understanding of U.S. Patent 5,462,932, including its legal scope, technological relevance, and influence within the neurotrophic drug development landscape.
More… ↓
⤷ Start Trial
|
